Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. Apontis Pharma AG
  6. News
  7. Summary
    APPH   DE000A3CMGM5

APONTIS PHARMA AG

(APPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

APONTIS PHARMA : announces launch of new Single Pill for more efficient treatment of hypertension and hyperlipidemia

09/14/2021 | 01:31am EDT

DGAP-News: APONTIS PHARMA AG / Key word(s): Product Launch
APONTIS PHARMA announces launch of new Single Pill for more efficient treatment of hypertension and hyperlipidemia

14.09.2021 / 07:30
The issuer is solely responsible for the content of this announcement.


APONTIS PHARMA announces launch of new Single Pill for more efficient treatment of hypertension and hyperlipidemia

Monheim am Rhein, 14 September 2021.
APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, today announced the signing of a new in-licensing agreement for a new Single Pill. The market launch in Germany is planned for early 2022.

The medication addresses patients who are simultaneously affected by hypertension (high blood pressure) and hyperlipidemia (disorder of lipid metabolism). The objective is to increase adherence by combining two active ingredients in just one pill and thus achieve a more efficient therapy for patients.

The success of the Single Pill therapy strategy was proven by the START study conducted in 2019. It showed that patients benefited from a Single Pill compared to a multi-pill regime with the same substances. Instead of taking several individual preparations, treatment with the combination of substances in a Single Pill, which combines up to three active substances, promises a much higher adherence to therapy. Consequently, medications are taken more reliably when the dosage form is limited to one pill.

APONTIS PHARMA is also pursuing this proven approach with its latest product and is offering a large and steadily increasing number of patients treatment perspective that meets their needs. Overall, APONTIS PHARMA is addressing a group of around half a million people in Germany who, in the case of hypertension and hyperlipidemia, have so far been taking a loose combination of these two substances. Accordingly, APONTIS PHARMA and the new Single Pill are opening up a promising market environment.

"As the Single Pill Company, our objective is to ensure the therapeutic success of patients through highly effective medications and to reduce costs for insurers to a minimum. We have many years of expertise in the so-called diseases of civilization and are now already launching the ninth Single Pill on the market. Hence, we are well on the way to achieving our ambitious goal of at least 20 Single Pill products by 2026," says Karlheinz Gast, Chief Executive Officer of APONTIS PHARMA AG.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three patent-free active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Deutschland
apontis-pharma.de/

APONTIS PHARMA Press Contact

CROSS ALLIANCE
Sven Pauly
Sara Pinto
ir@apontis-pharma.de
T: +49 89 125 09 0330



14.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: APONTIS PHARMA AG
Alfred-Nobel-Str. 10
40789 Monheim
Germany
E-mail: info@apontis-pharma.de
Internet: https://apontis-pharma.de/
ISIN: DE000A3CMGM5
WKN: A3CMGM
Listed: Regulated Unofficial Market in Frankfurt (Scale)
EQS News ID: 1233046

 
End of News DGAP News Service

1233046  14.09.2021 

fncls.ssp?fn=show_t_gif&application_id=1233046&application_name=news&site_id=zonebourse_sftp

© EQS 2021
All news about APONTIS PHARMA AG
09/14APONTIS PHARMA : To Launch New Single Pill For Hypertension, Hyperlipidemia
MT
09/14APONTIS PHARMA : announces launch of new Single Pill for more efficient treatment of hyper..
EQ
09/14PRESS RELEASE : APONTIS PHARMA announces launch of new Single Pill for more efficient trea..
DJ
09/14Apontis Pharma AG Announces Launch of New Single Pill for More Efficient Treatment of H..
CI
08/11APONTIS PHARMA : builds on strong position and profitability in first half of 2021 - preli..
EQ
08/11PRESS RELEASE : APONTIS PHARMA builds on strong position and profitability in first half o..
DJ
07/28APONTIS PHARMA : reports accelerated growth in first half of 2021 - Single Pill revenues +..
EQ
07/28PRESS RELEASE : APONTIS PHARMA reports accelerated growth in first half of 2021 - Single P..
DJ
07/28Apontis Pharma AG Provides Earnings Guidance for the Financial Year 2021
CI
07/28Apontis Pharma AG Announces Unaudited Preliminary Earnings Results for the First Half o..
CI
More news
Financials
Sales 2021 49,3 M 57,1 M 57,1 M
Net income 2021 1,55 M 1,80 M 1,80 M
Net cash 2021 27,5 M 31,9 M 31,9 M
P/E ratio 2021 133x
Yield 2021 -
Capitalization 209 M 243 M 243 M
EV / Sales 2021 3,69x
EV / Sales 2022 3,10x
Nbr of Employees 195
Free-Float 100%
Chart APONTIS PHARMA AG
Duration : Period :
Apontis Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 24,60 €
Average target price 36,50 €
Spread / Average Target 48,4%
EPS Revisions
Managers and Directors
Karlheinz Gast Chief Executive Officer
Edin Hadzic Chairman-Supervisory Board
Olaf Randerath Head-Medical Affairs
Olaf Elbracht Member-Supervisory Board
Christopher Friedel Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
APONTIS PHARMA AG0.00%243
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657